SI2585470T1 - Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze - Google Patents

Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze

Info

Publication number
SI2585470T1
SI2585470T1 SI201131094A SI201131094A SI2585470T1 SI 2585470 T1 SI2585470 T1 SI 2585470T1 SI 201131094 A SI201131094 A SI 201131094A SI 201131094 A SI201131094 A SI 201131094A SI 2585470 T1 SI2585470 T1 SI 2585470T1
Authority
SI
Slovenia
Prior art keywords
inhibition
tyrosine kinase
kinase activity
pyrimidine derivatives
fused pyrimidine
Prior art date
Application number
SI201131094A
Other languages
English (en)
Inventor
Mi Young Cha
Seok Jong Kang
Mi Ra Kim
Ju Yeon Lee
Ji Young Jeon
Myoung Gi Jo
Eun Joo Kwak
Kwang Ok Lee
Tae Hee Ha
Kwee Hyun Suh
Maeng Sup Kim
Original Assignee
Hanmi Science Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2585470(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co., Ltd. filed Critical Hanmi Science Co., Ltd.
Publication of SI2585470T1 publication Critical patent/SI2585470T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
SI201131094A 2010-06-23 2011-06-20 Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze SI2585470T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20100059686 2010-06-23
PCT/KR2011/004482 WO2011162515A2 (en) 2010-06-23 2011-06-20 Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity
EP11798350.2A EP2585470B1 (en) 2010-06-23 2011-06-20 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity

Publications (1)

Publication Number Publication Date
SI2585470T1 true SI2585470T1 (sl) 2017-03-31

Family

ID=45371929

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131644T SI2975042T1 (sl) 2010-06-23 2011-06-20 Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze
SI201131094A SI2585470T1 (sl) 2010-06-23 2011-06-20 Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201131644T SI2975042T1 (sl) 2010-06-23 2011-06-20 Novi fuzirani derivati pirimidina za inhibicijo aktivnosti tirozin kinaze

Country Status (31)

Country Link
US (4) US8957065B2 (sl)
EP (2) EP2975042B1 (sl)
JP (2) JP5834347B2 (sl)
KR (2) KR101587506B1 (sl)
CN (2) CN105061438B (sl)
AR (2) AR081978A1 (sl)
AU (1) AU2011269989B2 (sl)
BR (2) BR112012033253A2 (sl)
CA (1) CA2803056C (sl)
CY (1) CY1118750T1 (sl)
DK (2) DK2585470T3 (sl)
ES (2) ES2622138T3 (sl)
HK (1) HK1211575A1 (sl)
HR (2) HRP20170456T1 (sl)
HU (2) HUE032515T2 (sl)
IL (2) IL223689A (sl)
LT (2) LT2585470T (sl)
MX (2) MX342164B (sl)
MY (2) MY162132A (sl)
NZ (2) NZ627709A (sl)
PL (2) PL2585470T3 (sl)
PT (2) PT2585470T (sl)
RS (2) RS58265B1 (sl)
RU (2) RU2598852C2 (sl)
SG (1) SG186378A1 (sl)
SI (2) SI2975042T1 (sl)
TR (1) TR201821217T4 (sl)
TW (2) TWI528962B (sl)
UA (2) UA108889C2 (sl)
WO (1) WO2011162515A2 (sl)
ZA (1) ZA201209742B (sl)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2526771T1 (sl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
US8957065B2 (en) * 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
EP2627179A4 (en) * 2010-10-14 2014-04-02 Ariad Pharma Inc METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS
JP5999177B2 (ja) * 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CN105254616B (zh) 2011-07-27 2017-10-17 阿斯利康(瑞典)有限公司 取代的n‑(2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
KR101660145B1 (ko) * 2012-02-23 2016-09-26 다이호야쿠힌고교 가부시키가이샤 퀴놀릴피롤로피리미딜 축합환 화합물 또는 그의 염
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
MY194911A (en) 2012-06-04 2022-12-22 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2013184766A1 (en) * 2012-06-06 2013-12-12 Irm Llc Compounds and compositions for modulating egfr activity
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
PE20151495A1 (es) 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas
TWI558706B (zh) 2013-02-22 2016-11-21 Taiho Pharmaceutical Co Ltd A tricyclic compound and a tricyclic compound which can be produced by the production method
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
WO2015006754A2 (en) 2013-07-11 2015-01-15 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
EP3027192A4 (en) 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
EP2832358A1 (en) 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmaceutical kit for use in the treatment of colon and colorectal cancer
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
AU2014323777C1 (en) * 2013-09-18 2018-04-26 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US20160017431A1 (en) * 2014-03-28 2016-01-21 Driver Group Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
KR102139847B1 (ko) 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
MX2016014308A (es) * 2014-05-01 2017-01-27 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7.
AU2015266552A1 (en) * 2014-05-28 2016-12-01 Astellas Pharma Inc. Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CN107108649B (zh) * 2014-12-30 2019-08-09 韩美药品株式会社 用于制备噻吩并嘧啶化合物的新型方法及其中使用的中间体
KR20160082062A (ko) 2014-12-30 2016-07-08 한미약품 주식회사 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
CN105837572B (zh) * 2015-02-02 2019-04-19 四川大学 N-取代苯基酰胺衍生物及其制备方法和用途
WO2016141068A1 (en) 2015-03-03 2016-09-09 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
RU2572709C1 (ru) * 2015-03-03 2016-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции структурно-функциональных нарушений артериального русла у больных ревматоидным артритом
JP6457697B2 (ja) 2015-04-29 2019-01-23 カントン チョンション ファーマシューティカル カンパニー，リミティド キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
EP3799873A1 (en) 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
RU2018115334A (ru) 2015-10-09 2019-11-11 Ацея Терапьютикс, Инк. Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
KR20170050453A (ko) * 2015-10-30 2017-05-11 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체
CN108137614B (zh) * 2015-12-02 2021-01-05 深圳市塔吉瑞生物医药有限公司 一种稠合嘧啶化合物及包含该化合物的组合物及其用途
US10829495B2 (en) 2015-12-03 2020-11-10 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
JP6978003B2 (ja) * 2015-12-03 2021-12-08 チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド 複素環式化合物およびその使用
AU2016382384A1 (en) * 2015-12-31 2018-07-12 Hanmi Pharm. Co., Ltd. Crystalline forms of hydrochloride salts of thienopyrimidine compound
JP2019504046A (ja) * 2015-12-31 2019-02-14 ハンミ ファーマシューティカルズ カンパニー リミテッド チエノピリミジン化合物の結晶形
WO2017122175A1 (en) 2016-01-13 2017-07-20 Acerta Pharma B.V. Therapeutic combinations of an antifolate and a btk inhibitor
US20190125751A1 (en) * 2016-05-18 2019-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2017204582A1 (en) * 2016-05-27 2017-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof inhibiting growth of cancer cells and a stabilizer having low melting point
SG11201811470PA (en) * 2016-06-30 2019-01-30 Daewoong Pharmaceutical Co Ltd Pyrazolopyrimidine derivatives as kinase inhibitor
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
AU2017295038B2 (en) 2016-07-15 2022-09-22 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
US20190201409A1 (en) 2016-09-19 2019-07-04 Mei Pharma, Inc. Combination therapy
CN106565612B (zh) * 2016-10-25 2018-10-16 大连医科大学 二苯乙烯基嘧啶类化合物，组合物及其用途
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
US20190376971A1 (en) 2017-01-19 2019-12-12 Acerta Pharma B.V. Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
WO2018139883A1 (ko) * 2017-01-26 2018-08-02 부광약품 주식회사 다중 표적 키나아제 저해제로서 융합피리미딘 유도체
CN106831814B (zh) * 2017-02-15 2018-11-23 山东大学 一种噻吩并[3,2-d]嘧啶类HIV-1逆转录酶抑制剂及其制备方法和应用
CN106916112B (zh) * 2017-03-02 2019-12-20 四川海思科制药有限公司 嘧啶衍生物及其制备方法和在医药上的应用
CN106866699B (zh) * 2017-03-29 2019-03-08 山东大学 一种二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
JP2020516682A (ja) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
CN108727382B (zh) * 2017-04-19 2022-07-19 华东理工大学 作为btk抑制剂的杂环化合物及其应用
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN109206435B (zh) * 2017-06-29 2020-09-08 中国医药研究开发中心有限公司 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019034153A1 (zh) * 2017-08-18 2019-02-21 北京韩美药品有限公司 一种化合物，其药物组合物及其用途及应用
CN109575045B (zh) * 2017-09-28 2021-02-12 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
KR102613433B1 (ko) * 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
BR112020009361A2 (pt) 2017-11-17 2020-10-13 Cellix Bio Private Limited composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2019120121A1 (zh) 2017-12-21 2019-06-27 深圳市塔吉瑞生物医药有限公司 用于抑制激酶活性的二苯氨基嘧啶类化合物
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
MX2020006799A (es) * 2017-12-28 2020-09-03 Daewoong Pharmaceutical Co Ltd Derivados de oxi-fluoropiperidina como inhibidor de cinasa.
SI3784663T1 (sl) 2018-04-23 2023-11-30 Celgene Corporation Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
PE20210406A1 (es) 2018-07-25 2021-03-02 Novartis Ag Inhibidores de inflamasoma nlrp3
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
CN109265469A (zh) * 2018-11-12 2019-01-25 大连医科大学附属第医院 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途
KR20200114776A (ko) * 2019-03-29 2020-10-07 한미약품 주식회사 퓨로피리미딘 화합물의 산 부가염의 결정형
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN111909101B (zh) * 2019-05-10 2022-07-19 浙江大学 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
EP3978496A4 (en) * 2019-05-31 2022-08-17 Haisco Pharmaceuticals Pte. Ltd. BTK INHIBITOR RING DERIVATIVES, METHOD OF MANUFACTURE THEREOF AND PHARMACEUTICAL USE THEREOF
AU2020298444A1 (en) * 2019-06-20 2021-12-02 Board Of Regents Of The University Of Texas System Small molecule inhibitors of SRC tyrosine kinase
CN110372529B (zh) * 2019-08-08 2022-05-24 黄河水利职业技术学院 N-[(3,4,5-三氟)苯基]丙烯酰胺及其制备方法
CN110511994B (zh) * 2019-09-09 2023-05-26 中南大学湘雅二医院 miRNA-4769-3p及其同源物的应用
CN115087655A (zh) * 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物
CN116057045A (zh) 2020-06-05 2023-05-02 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
CN111732597B (zh) * 2020-06-20 2022-11-01 江西科技师范大学 含4-酰胺苯氧基的2-氨基嘧啶杂环类化合物的制备及应用
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
EP4238975A1 (en) * 2020-10-29 2023-09-06 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP2007502819A (ja) * 2003-08-19 2007-02-15 ワイス・ホールディングズ・コーポレイション ４−アミノ−３−キノリンカルボニトリルの調製方法
WO2007089768A2 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
JP2008013527A (ja) 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
JP5500990B2 (ja) 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EP3109249A1 (en) 2007-11-15 2016-12-28 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
BRPI0911228A2 (pt) * 2008-04-07 2017-05-30 Irm Llc compostos e composições como inibidores de proteínas quinase
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US8957065B2 (en) * 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
AU2012311184A1 (en) * 2011-09-22 2014-03-06 Pfizer Inc. Pyrrolopyrimidine and purine derivatives

Also Published As

Publication number Publication date
MX2012014601A (es) 2013-02-21
EP2975042B1 (en) 2018-10-03
CN105061438B (zh) 2017-07-04
CN102947316A (zh) 2013-02-27
KR101589114B1 (ko) 2016-01-29
KR101587506B1 (ko) 2016-01-25
HUE032515T2 (en) 2017-09-28
US20160229868A1 (en) 2016-08-11
TR201821217T4 (tr) 2019-01-21
PT2585470T (pt) 2017-03-06
RU2585177C2 (ru) 2016-05-27
MX342164B (es) 2016-09-19
USRE46511E1 (en) 2017-08-15
US8957065B2 (en) 2015-02-17
KR20110139653A (ko) 2011-12-29
BR122014012788A2 (pt) 2019-08-13
RU2598852C2 (ru) 2016-09-27
TW201204364A (en) 2012-02-01
CY1118750T1 (el) 2017-07-12
NZ627709A (en) 2014-12-24
CN102947316B (zh) 2016-08-10
US20130116213A1 (en) 2013-05-09
SG186378A1 (en) 2013-01-30
RS58265B1 (sr) 2019-03-29
HRP20190012T1 (hr) 2019-02-22
JP5834347B2 (ja) 2015-12-16
UA108889C2 (uk) 2015-06-25
AU2011269989A1 (en) 2013-02-07
IL223689A (en) 2017-03-30
PL2585470T3 (pl) 2017-07-31
CA2803056C (en) 2017-05-16
DK2975042T3 (en) 2019-01-21
BR122014012788B1 (pt) 2022-04-19
ES2703552T3 (es) 2019-03-11
RU2013102881A (ru) 2014-07-27
BR112012033253A2 (pt) 2016-11-22
RS55783B1 (sr) 2017-07-31
EP2585470B1 (en) 2017-01-25
AR081978A1 (es) 2012-10-31
US9345719B2 (en) 2016-05-24
PL2975042T3 (pl) 2019-07-31
TW201443059A (zh) 2014-11-16
RU2014147193A (ru) 2015-07-10
HRP20170456T1 (hr) 2017-05-19
TWI528962B (zh) 2016-04-11
PT2975042T (pt) 2019-01-11
MY162132A (en) 2017-05-31
NZ605988A (en) 2014-11-28
ZA201209742B (en) 2014-03-26
ES2622138T3 (es) 2017-07-05
EP2975042A1 (en) 2016-01-20
JP2013529630A (ja) 2013-07-22
CN105061438A (zh) 2015-11-18
TWI513701B (zh) 2015-12-21
JP5852173B2 (ja) 2016-02-03
SI2975042T1 (sl) 2019-02-28
DK2585470T3 (en) 2017-04-10
KR20140060473A (ko) 2014-05-20
LT2975042T (lt) 2019-01-25
LT2585470T (lt) 2017-04-10
AU2011269989B2 (en) 2014-12-11
HUE042165T2 (hu) 2019-06-28
IL232382A0 (en) 2014-06-30
AR096075A2 (es) 2015-12-02
US20150045324A1 (en) 2015-02-12
MY174196A (en) 2020-03-13
WO2011162515A3 (en) 2012-05-03
IL232382A (en) 2016-12-29
JP2014159473A (ja) 2014-09-04
AU2011269989A8 (en) 2013-02-28
WO2011162515A2 (en) 2011-12-29
CA2803056A1 (en) 2011-12-29
HK1211575A1 (en) 2016-05-27
EP2585470A4 (en) 2014-01-01
UA111272C2 (uk) 2016-04-11
EP2585470A2 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
HRP20190012T1 (hr) Novi fuzionirani pirimidin derivati za inhibiciju aktivnosti tirozin kinaze
HK1186186A1 (en) Inhibitors of brutons tyrosine kinase
HK1205431A1 (en) Solid forms of an epidermal growth factor receptor kinase inhibitor
HK1194381A1 (en) Inhibitors of brutons tyrosine kinase
EP2632898A4 (en) HETEROCYCLIC TYROSINE KINASE HEMMER
IL213906A0 (en) Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
HK1197060A1 (en) Inhibitors of brutons tyrosine kinase
ZA201303614B (en) Quinazolin-4(3h)-one derivatives used as p13 kinase inhibitors
ZA201309702B (en) Inhibitors of lrrk2 kinase activity
HK1198168A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
EP2593462A4 (en) NEW CONDENSED HETEROCYCLIC DERIVATIVES SUITABLE AS C-MET TYROSINE KINASE HEMMER
ZA201500471B (en) Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof
HK1200816A1 (en) Inhibitors of brutons tyrosine kinase
IL218790A0 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
ZA201207482B (en) Inhibitors of protein tyrosine kinase activity
EP2754659A4 (en) 4-SUBSTITUTED- (3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO) -PYRIMIDINES DERIVATIVES HAVING PROTEIN KINASE INHIBITION ACTIVITY AND USE THEREOF
IL244032B (en) Intermediates for the preparation of pyrazolylquinoxaline kinase inhibitors
AU2013201520B9 (en) Solid forms of an epidermal growth factor receptor kinase inhibitor